These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25695333)

  • 1. Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf.
    Samadani R; Zhang J; Brophy A; Oashi T; Priyakumar UD; Raman EP; St John FJ; Jung KY; Fletcher S; Pozharski E; MacKerell AD; Shapiro P
    Biochem J; 2015 May; 467(3):425-38. PubMed ID: 25695333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress.
    Martinez R; Huang W; Samadani R; Mackowiak B; Centola G; Chen L; Conlon IL; Hom K; Kane MA; Fletcher S; Shapiro P
    J Pharmacol Exp Ther; 2021 Jan; 376(1):84-97. PubMed ID: 33109619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.
    Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Bräse S; Ibrahim MAA; Nieger M; Garvalov BK; Dalby KN; Kaoud TS
    Bioorg Chem; 2019 Feb; 82():290-305. PubMed ID: 30396063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation.
    Crowe MS; Zavorotinskaya T; Voliva CF; Shirley MD; Wang Y; Ruddy DA; Rakiec DP; Engelman JA; Stuart DD; Freeman AK
    Mol Cancer Res; 2021 Jun; 19(6):1063-1075. PubMed ID: 33707308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
    Choi WK; El-Gamal MI; Choi HS; Baek D; Oh CH
    Eur J Med Chem; 2011 Dec; 46(12):5754-62. PubMed ID: 22014559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel extracellular signal-regulated kinase docking domain inhibitors.
    Hancock CN; Macias A; Lee EK; Yu SY; Mackerell AD; Shapiro P
    J Med Chem; 2005 Jul; 48(14):4586-95. PubMed ID: 15999996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.
    Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M
    Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors.
    Marchetti P; Trinh A; Khamari R; Kluza J
    Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):999-1005. PubMed ID: 29413908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
    Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
    Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
    Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
    El-Nassan HB
    Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ERK beyond the boundaries of the kinase active site in melanoma.
    Sammons RM; Ghose R; Tsai KY; Dalby KN
    Mol Carcinog; 2019 Sep; 58(9):1551-1570. PubMed ID: 31190430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.